Author Affiliations: Departments of Pediatrics and Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY (Dr Moscona); and Molecular and Health Technologies, Parkville, South Victoria, Australia (Dr McKimm-Breschkin).
During the last 2 years, the medical community has been tensely following the emergence of resistance to oseltamivir in strains of influenza A.1 The clinical relevance and transmissibility of these resistant variants has been unknown, and planning for epidemic and pandemic influenza thus far has ignored the issue due to lack of evidence that it will be of medical consequence. Neuraminidase inhibitors are presently the only reliable antiviral option for treatment of influenza infection: the usefulness of the adamantanes (amantadine and rimantidine) has been virtually eliminated by the development of resistance.2 Until now, little spontaneous resistance to neuraminidase inhibitors has been documented, and no spontaneously resistant influenza viruses were identified in the world prior to the introduction of the drugs. This may now be changing.
Moscona A, McKimm-Breschkin J. News About Influenza B Drug Resistance That Cannot Be Ignored. JAMA. 2007;297(13):1492–1493. doi:https://doi.org/10.1001/jama.297.13.1492
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: